Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Politics

Biden’s pandemic playbook failed. Trump just offered a smarter path forward

by May 15, 2025
May 15, 2025
Biden’s pandemic playbook failed. Trump just offered a smarter path forward

NEWYou can now listen to Fox News articles!

On May 5, President Donald Trump signed an executive order outlawing future federal funds going to gain-of-function research. This move comes as the nation begins to reckon with the broader failures of its pandemic response – failures that extended far beyond the lab and into every aspect of public health policy.

As the acute phase of the COVID-19 pandemic fades into the rearview mirror, the United States finds itself engaged in postmortems: on lockdowns, vaccines, school closures and public trust. But there’s one glaring lesson the U.S. has yet to fully absorb – its health strategy during crises can’t rely on just one type of tool. A narrow, binary response to COVID-19 cost lives. The country must do better next time.

During the pandemic, the public was often presented with a simple directive: get vaccinated or take your chances. While most Americans indeed should have gotten vaccinated, policymakers should have provided more room for nuance and variation. They ignored a core truth of medicine – no single solution fits every individual. The virus evolved. Patient responses varied. But the official toolkit did not adapt.

What the U.S. needed (and still needs) is a robust, flexible public health approach that supports a range of modalities: vaccines, yes, but also antivirals, monoclonal antibodies (mAbs) and emerging biologics. 

A resilient system is one that can pivot quickly, match patients with the right intervention and adapt as science advances.

Monoclonal antibodies offer a clear example of what went wrong. These therapies, proven to reduce hospitalizations and deaths among high-risk patients, were widely distributed early in the pandemic and used successfully by top federal officials, including the president. But in late 2021 and early 2022, federal authorities stopped distributing them, citing reduced efficacy against new variants.

This was a mistake. mAbs are a platform technology. They can be tailored to variants and deployed quickly. They are especially important for those who don’t respond well to vaccines. But nearly five years after the start of the pandemic, no mAb has received full FDA approval for respiratory virus prevention despite meeting the same safety and efficacy benchmarks used to fast-track other medical countermeasures. 

Trump signs executive order lowering pharmaceutical drug prices for Americans

Meanwhile, the public was encouraged to rely on booster shots which, while still additive, lost efficacy as the pandemic continued. CDC data show that the bivalent booster provided only 37% protection against hospitalization for adults over 65 after several months. For the immunocompromised, protection was even lower. Yet, therapies that could have closed that gap were taken off the table.

The U.S. should have maintained an all-of-the-above approach to treatment so its health professionals could make patient recommendations on a case-by-case basis, ensuring the most vulnerable Americans receive adequate protection. 

More broadly, five years later, the U.S. still lacks a proactive framework for deploying flexible, evidence-driven therapeutics in a public health emergency. The U.S. needs a system that doesn’t just rely on whatever is first to market; it needs one that actively supports a diversified portfolio of tools.

That means empowering agencies like the Biomedical Advanced Research and Development Authority and the National Institutes of Health to invest in adaptable countermeasures – antibody platforms, broad-spectrum antivirals, rapid diagnostics and therapeutic RNA technologies. It also means modernizing the FDA’s approval pathways to reflect the pace of innovation. When real-world evidence shows that a therapy is saving lives, regulators should have the flexibility to act.

Trump bans funding for gain-of-function research possibly responsible for COVID-19 pandemic

Congress can help by authorizing funding streams that reward versatility, creating incentives for companies to maintain and adapt an all-of-the-above treatment approach, and ensuring public-private partnerships are built for speed and scale. Legislation could also establish a standing procurement mechanism for variant-specific updates, not just vaccines.

All of this will help to mitigate the damage of one of the greatest casualties of the pandemic – the decline of public trust in America’s health institutions. This erosion stemmed from the sense that key decisions lacked transparency or failed to account for patients’ diverse needs.

According to a 2022 Pew Research Center survey, only 29% of U.S. adults said they had a great deal of confidence in medical scientists, down from 40% at the beginning of the pandemic. Trust in public health officials followed a similar decline.

David Zweig: Closing Schools During Covid Was The Most Catastrophic Consequence Of Interventions

A more transparent, inclusive approach, where policymakers communicate the rationale behind treatment shifts and openly assess real-world outcomes, can help rebuild that trust. A better system would emphasize data-sharing, clear communication, and respect for physician judgment in tailoring care to patient needs.

COVID-19 exposed the limits of the U.S.’ current playbook. A more effective future demands flexibility, pluralism and the humility to admit health policymakers don’t always know right away what will work best, or for whom. 

But if regulators build the right system – one that encourages innovation, evaluates outcomes in real time, and keeps every safe and effective tool on the table – they won’t have to learn this lesson again the hard way.

This post appeared first on FOX NEWS
previous post
YouTube will stream NFL Week 1 game in Brazil for free
next post
GOP reps, advocacy group to target competitive House districts in Trump tax-cut push

Related Posts

Biden calls Russia prisoner swap deal that freed...

August 1, 2024

‘Dangerous’ order by liberal judge to rehire federal...

March 17, 2025

Biden admin officials noticed stamina issues in president’s...

December 19, 2024

The Speaker’s Lobby: A Universal Interest

June 29, 2024

‘Dead of night’: Dems accuse GOP of cowardice...

May 20, 2025

American Library Association claims ‘censoring’ sexually explicit books...

April 10, 2024

One-man Cabinet: Marco Rubio went from rival to...

May 8, 2025

White House lawyers who advised Reagan, Bush endorse...

August 23, 2024

‘UN80 Initiative’ appears to show world body’s panic...

March 12, 2025

Trump clarifies he meant Cheney wouldn’t have ‘guts’...

November 2, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • Home Depot is buying GMS for about $4.3 billion as retailer chases more home pros

      June 30, 2025
    • Trump signs order lifting sanctions on Syria

      June 30, 2025
    • Trump’s ‘big, beautiful bill’ hits another snag in House as conservative caucus raises red flag

      June 30, 2025
    • ‘Antisemitic’ British band banned from US after viral ‘death to the IDF’ festival chants

      June 30, 2025
    • White House says Mamdani would ‘crush’ New York City if elected mayor

      June 30, 2025
    • Trump to sign order lifting sanctions on Syria

      June 30, 2025

    Categories

    • Business (1,286)
    • Politics (6,216)
    • Stocks (904)
    • World News (460)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved